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Polyoma virus is highly oncogenic when inoculated into immunocompromised adult mice and neonatal mice of specific
inbred strains. Although T lymphocytes are known to be essential in controlling polyoma virus tumorigenesis, the importance
of class I MHC-restricted CD81 T cells in mediating tumor resistance remains unclear. Here, we investigated the tumori-
genicity of polyoma virus in adult mice rendered CD81 T cell-deficient by homozygous (2/2) disruption of the b2-
microglobulin (b2m) or CD8a (CD8) genes. Nearly all (94%) of the virus-infected adult C57BL/6b2m
2/2 mice developed
tumors, and 20% of the virus-inoculated adult C57BL/6CD82/2 mice developed hindlimb paralysis, which is indicative of
vertebral tumors. Only 2 of 20 virus-inoculated adult normal C57BL/6 mice developed tumors. Despite these different tumor
susceptibilities, persistent viral DNA was detected in multiple organs of mice of all three strains. Multifocal lymphoplasma-
cytic interstitial infiltrates were present in the kidneys and lungs of virus-infected C57BL/6b2m
2/2 and in the lungs of
virus-inoculated C57BL/6CD82/2 mice. These infiltrates were composed primarily of B cells and colocalized with staining for
the major viral capsid protein, VP1. No infiltrates or VP1 staining was detected in the kidneys of infected C57BL/6 mice. Using
a highly sensitive RT-PCR bioluminescence immunoassay, we investigated and detected persistent polyoma T protein and
VP1 messages in both C57BL/6b2m
2/2 and C57BL/6 mice. C57BL/6b2m
2/2 and C57BL/6 mice had equivalent serum
virus-neutralizing antibody titers. These results provide in vivo evidence that class I MHC-restricted CD81 T cells are involved
in mediating protection against polyoma virus tumor development. © 1998 Academic Press
INTRODUCTION
Polyoma virus is a natural mouse papovavirus that
expresses potent oncogenicity when inoculated into im-
munocompromised adult mice and newborn mice of par-
ticular inbred strains (Dawe et al., 1987; Law et al., 1967).
More than 30 distinct cell types may be infected by the
virus, and up to a dozen different virus-induced epithelial
and mesenchymal tumors appear within 2–4 months
after inoculation (Dawe et al., 1987). The susceptibility of
congenitally athymic and neonatally thymectomized mice
to polyoma-induced tumors (Allison et al., 1974; Law,
1966) and the inability of passively transferred hyperim-
mune antiviral sera to prevent tumors (Allison and Law,
1968) illustrate the essential role of T cells in controlling
polyoma virus tumorigenesis. Since these early studies,
however, the identity of the T cell subset or subsets
responsible for mediating tumor resistance remain un-
clear.
Several recent studies have implicated class I MHC-
restricted CD81 T cells as anti-polyoma tumor immune
effectors. CD81 T cell depletion of virus-immune mice
has been shown to block rejection of a polyoma tumor
challenge (Ljunggren et al., 1994), and immunization with
a synthetic class I MHC-binding peptide corresponding
to a polyoma protein sequence protected mice from a
challenge with a polyoma DNA-transfected lymphoma
(Berke et al., 1996a). Additionally, we reported that the
high tumor susceptibility of neonatally infected H-2k hap-
lotype mice of particular strains resulted from the inher-
itance of the Mtv-7 mouse mammary tumor virus provi-
rus, whose superantigen appears to create a hole in the
T cell repertoire for anti-polyoma CD81 CTL (Lukacher et
al., 1993, 1995). Recent studies have confirmed that the
polyoma tumor susceptibility of neonatally infected
H-2kMtv-71 mice is associated with a weak anti-polyoma
class I MHC-restricted CTL response (Lukacher and Wil-
son, 1998).
To directly assess the contribution of CD81 T cells to
polyoma tumor resistance, we investigated the capacity
of polyoma virus to induce tumors in mice homozygous
for a targeted disruption (knockout) of the b2-microglobu-
lin (b2m) or CD8a genes. In this report, we demonstrate
that b2m
2/2 mice are highly susceptible to polyoma virus
tumor development and have persistent polyoma virus
DNA and protein message in multiple organs. CD82/2
mice show lower susceptibility to polyoma virus tumori-
genesis and maintain persistent virus infection. Unex-
pectedly, persistent viral DNA and early and late protein
messages were also detected in normal syngeneic mice,
despite their high polyoma tumor resistance. The impli-
cations of these findings to the mechanisms of CD81 T
cell control of polyoma virus-induced tumors are dis-
cussed.
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RESULTS
Polyoma tumor susceptibility of virus-infected b2m
2/2
mice
To determine whether a deficiency in CD81 class I
MHC-restricted T cells renders mice susceptible to poly-
oma virus tumorigenesis, adult C57BL/6b2m
2/2, C57BL/
6CD82/2, and C57BL/6 mice were inoculated intraperi-
toneally with the high tumor-producing A2 strain of poly-
oma virus (Dawe et al., 1987). Consistent with other
studies documenting the marked resistance of C57BL/6
mice to polyoma virus-induced tumors (Freund et al.,
1992; Law et al., 1967), only 2 of 20 virus-inoculated
C57BL/6 mice developed isolated bone tumors 8 months
p.i. (Table 1). The emergence of these bone tumors,
which expressed T and VP1 proteins (data not shown), is
consistent with the apparent predilection for persistent
viral DNA and message in bone (see below).
In contrast, 26 of 28 b2m
2/2 mice developed overt
bilateral salivary gland tumors by 9–15 weeks p.i. (Table
1). Complete necropsies of these tumor-bearing mice
revealed the only other tumor histotype as an isolated
bone tumor of the sternum, although one salivary tumor-
bearing and one overtly tumor-free b2m
2/2 mouse also
developed hindlimb paralysis, which is indicative of a
vertebral bone tumor (Harper et al., 1983; Wirth et al.,
1992). Only one virus-infected b2m
2/2 mouse remained
asymptomatic for the entire 28-week observation period,
although PCR analysis revealed persistent polyoma virus
DNA in multiple organs in this animal (see below).
Polyoma tumor incidence in CD82/2 mice
In view of a previous study (Berke et al., 1996b) report-
ing a low tumor incidence in neonatally virus-infected
CD82/2 mice, we were surprised to find that b2m
2/2
mice are highly susceptible to polyoma virus-induced
tumors. To exclude the possibility that other factors, such
as differences in size of virus inoculum and age at time
of inoculation, were responsible for this apparent dis-
crepancy, we inoculated 15 adult CD82/2 and 6 adult
b2m
2/2 mice with polyoma virus and monitored them for
22 weeks for the development of polyoma tumors (Table
2). Five of the six b2m
2/2 mice developed bilateral sali-
vary gland tumors by 16–20 weeks p.i. In contrast, none
of the CD82/2 mice developed overt tumors, although 3
of the 15 mice developed hindlimb paralysis, indicative of
a polyoma-induced vertebral tumor (Harper et al., 1983;
Wirth et al., 1992), by 12–18 weeks p.i. Histological ex-
amination, however, failed to identify polyoma tumors in
any of the virus-inoculated CD82/2 mice. These results
are similar to those of Berke et al. (1996b), who reported
a low tumor incidence in neonatally virus-infected
CD82/2 mice.
Antiviral antibody responses in b2m
2/2 mice
To exclude the possibility that a deficiency in the
anti-polyoma antibody response accounted for the high
polyoma tumor susceptibility of b2m
2/2 mice, serum
virus-neutralizing antibody responses from infected
C57BL/6 and b2m
2/2 mice were compared. Serum from
four infected b2m
2/2 and three infected C57BL/6 mice
reduced virus plaque formation by 50% at a dilution of
1:40,000. Serum from uninfected mice of both strains had
no inhibitory effect on virus plaque formation. Western
blot analysis using serum from infected b2m
2/2 mice to
probe whole-cell lysates from uninfected and virus-in-
fected cells also demonstrated that b2m
2/2 mice mount
antibody responses against each of the T proteins and
VP1 protein (data not shown).
TABLE 2
Susceptibility to Polyoma Virus-Induced Tumors
in C57BL/6CD82/2 Mice
Mouse strain
C57BL/6b2m
2/2 C57BL/6CD82/2
Fraction of mice with
tumor(s) 5/6 0/15a
Interval from infection to
necropsy in tumor-
bearing mice (weeks)
Mean 18
Range 16–20
Note. C57BL/6b2m
2/2 and C57BL/6CD82/2 mice were inoculated
intraperitoneally with 1.5 3 106 PFU of polyoma virus. The mice were
monitored for 22 weeks for the development of tumors.
a Three C57BL/6CD82/2 mice developed hindlimb paralysis at 12–18
weeks p.i., although histological examination failed to reveal tumors in
these mice.
TABLE 1
Polyoma Virus Tumorigenesis in C57BL/6b2m
2/2 Mice
Mouse strain
C57BL/6 C57BL/6b2m
2/2
Fraction of mice with tumor(s) 2/20 26/28a
Interval from infection to
necropsy in tumor-bearing
mice (weeks)
Mean 31 11
Range 30–32 9–15
Note. C57BL/6 and C57BL/6b2m
2/2 mice were inoculated intraperi-
toneally with 1.5 3 106 PFU of polyoma virus. C57BL/6 mice were
monitored for 33 weeks and C57BL/6b2m
2/2 mice were monitored for
28 weeks for the development of tumors.
a Twenty-six of 28 b2m
2/2 mice developed bilateral salivary gland
tumors. One tumor-free b2m
2/2 mouse exhibited hindlimb paralysis at
8 weeks p.i., indicative of a vertebral polyoma-induced tumor (Harper et
al., 1983; Wirth et al., 1992).
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Renal lesions in polyoma virus-infected b2m
2/2 and
CD82/2 mice
Histological examination of tissue sections from per-
sistently infected C57BL/6, CD82/2, and b2m
2/2 mice
revealed multifocal interstitial lymphoplasmacytic infil-
trates in the kidneys of nearly all of the b2m
2/2 (Figs. 1C
and 1D) and CD82/2 mice (data not shown). Similar
infiltrates were also seen in the lung interstitium of ap-
proximately half of the tumor-bearing b2m
2/2 mice (data
not shown). These kidney infiltrates were absent in un-
infected b2m
2/2 (Fig. 1A), infected C57BL/6 mice (Fig.
1B), and in the single asymptomatic, virus-infected
b2m
2/2 mouse (data not shown).
Immunohistochemical staining of kidney sections from
tumor-bearing b2m
2/2 mice showed that the infiltrates
were composed predominantly of B cells (Fig. 2A) and
scattered T cells (Fig. 2B). The focal distribution of these
B cell-rich infiltrates in CD81 T cell-deficient mice raised
the possibility of an in situ antiviral antibody response.
This notion is strongly supported by the finding of immu-
noreactivity for VP1, the major viral capsid protein, in the
nuclei of tubule epithelial cells associated with the inter-
stitial infiltrates (Fig. 2C). The presence of VP1 is taken
as evidence of productive polyoma virus infection in
b2m
2/2 mice (Atencio et al., 1993). Immunohistochemi-
cal staining for VP1 protein in the kidneys of virus-
infected C57BL/6 mice was negative (Fig. 2D). Western
immunoblot assay of kidney lysates from persistently
infected b2m
2/2 and C57BL/6 mice also failed to detect
VP1 protein (data not shown).
Polyoma virus DNA persistence
The presence of VP1-positive cells in the kidneys of
b2m
2/2 mice prompted us to investigate whether poly-
oma virus DNA persisted in other organs in b2m
2/2 and
CD82/2 mice. Persistent virus DNA was not detected in
tissue samples from b2m
2/2 mice by Southern blot anal-
ysis (data not shown) or in C57BL/6, CD82/2, or b2m
2/2
mice using conventional PCR to amplify a 317-bp product
from the noncoding region and proximal T protein coding
sequence of the polyoma virus genome (data not shown).
In contrast, when a multistep thermocycling protocol
(see Materials and Methods) was included before PCR
amplification to increase the efficiency of the PCR, per-
FIG. 1. Histological changes in the kidneys of polyoma virus-infected b2m
2/2 mice. Mononuclear interstitial lymphoplasmacytic infiltrates are
absent in the kidneys of uninfected b2m
2/2 (A) and 6-week p.i. C57BL/6 (B) mice but are present in the kidneys of 8- to 15-week p.i. b2m
2/2 mice
(C and D). Magnifications: A–C, 340; D, 3400.
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sistent polyoma virus DNA was detected in multiple
organs of mice of all three strains (Table 3). No polyoma
virus DNA PCR amplicon was generated using genomic
DNA from uninfected mice (data not shown). The integrity
of the genomic DNA from each organ was confirmed by
PCR amplification of a 330-bp product using a mouse
chromosome 11 simple sequence repeat primer set
(data not shown).
Table 3 summarizes the multiple and variable sites of
persistent polyoma virus DNA in three tumor-bearing
b2m
2/2 mice and the two tumor-free b2m
2/2 mice. In-
terestingly, no viral DNA was detected in the salivary
glands of the asymptomatic, tumor-free b2m
2/2 mouse
(mouse 5). b2m
2/2 mouse 4, killed early due to hindlimb
paralysis, would likely have developed a salivary gland
tumor given the presence of persistent virus DNA in this
organ. In light of reports describing the absence of PCR-
amplifiable polyoma DNA in adult CD82/2 and normal
C57BL/6 mice 1 month after infection (Berke et al., 1995),
we were surprised to discover persistent polyoma DNA
in C57BL/6 mice as late as 9 weeks p.i. and in CD82/2
mice as late as 22 weeks p.i. (Table 3). In both b2m
2/2
and C57BL/6 mice, bone, heart, and kidney were the
most frequent sites of virus DNA persistence. A clear-cut
difference in the organ distribution of persistent polyoma
DNA between C57BL/6 and b2m
2/2 mice was the lung,
which was positive in all b2m
2/2 mice but negative for all
C57BL/6 mice.
Persistent polyoma protein message in C57BL/6 and
b2m
2/2 mice
The absence of immunohistochemically detectable
polyoma VP1 protein in the kidneys of infected C57BL/6
mice (Fig. 2D), despite the presence of persistent poly-
oma DNA (Table 3), raised the possibility that productive
viral infection may also persist in C57BL/6 mice but at
lower levels than in b2m
2/2 mice. Given the paucity of
VP1-positive cells in the kidneys of b2m
2/2 mice (Fig.
2C), we used a novel highly sensitive RT-PCR biolumi-
nescence immunoassay (Actor et al., 1998) to examine
organs of C57BL/6 and b2m
2/2 mice frequently contain-
ing persistent virus DNA (heart, kidney, bone; see Table
3) for the presence of polyoma T and VP1 protein mes-
FIG. 2. Lymphoplasmacytic infiltrates in the kidneys of polyoma virus-infected b2m
2/2 mice colocalize with staining for the polyoma VP1 protein.
Kidney sections of 8- to 13-week p.i. b2m
2/2 mice were stained with anti-B220 monoclonal antibody (A), anti-CD5 monoclonal antibody (B), and rabbit
anti-polyoma VP1 anti-sera (C). (D) Kidney section of a 6-week p.i. C57BL/6 mouse. Magnifications: A–C, 3200; D, 3100.
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sages. T protein message was detected with low-cycle
(23 cycles) PCR amplification in 6-week p.i. mice of both
strains (Fig. 3). As this cycle number falls within the
linear phase of PCR amplification (Actor et al., 1998), the
T protein message levels in the different organs within
and between individual mice could be directly compared.
Although the relative levels of transcripts among the
tested organs for each mouse varied, as a group, 2- to
5-fold higher message levels were found in b2m
2/2 mice
than in C57BL/6 mice (Fig. 3). Although T protein mes-
sage was revealed by 23 cycles of PCR amplification, no
VP1 message was detected at 23 cycles. VP1 transcripts
were revealed, however, at 40 cycles in all of the sam-
ples from virus-infected b2m
2/2 mice and in samples
from two of the three virus-infected C57BL/6 mice (Fig. 3).
This indicates that productive polyoma infection per-
sisted in tumor-resistant C57BL/6 mice as well as in
tumor-susceptible b2m
2/2 mice, although conclusions
about relative message levels cannot be drawn because
this high cycle number resides in the plateau phase of
PCR amplification (Actor et al., 1998). Nevertheless, the
necessity for high-cycle PCR amplification to detect VP1
messages suggests a lower representation of cDNA for
VP1 than T protein in organs persistently infected by
polyoma virus.
DISCUSSION
The high polyoma tumor susceptibility of b2m
2/2 mice
described here provides in vivo evidence for class I
MHC-restricted cytotoxic T lymphocyte-mediated protec-
tion against polyoma virus-induced tumors. Despite op-
posite tumor susceptibilities, both virus-inoculated
C57BL/6b2m
2/2 and normal C57BL/6 mice had persis-
tent polyoma virus DNA and T and VP1 protein mes-
sages. In addition,b2m
2/2 and C57BL/6 mice mounted
equivalent serum virus-neutralizing antibody responses,
confirming early studies that humoral immunity does not
TABLE 3
Persistence of Polyoma Virus DNA
Organ
C57BL/6a C57BL/6b2m
2/2b C57BL/6CD82/2c
1 2 3 4 1 2 3 4 5 1 2 3
Bone 1 1 1 1 1 1 1 1 2 ND ND ND
Brain 2 2 1 2 1 2 2 1 2 ND ND ND
Heart 1 1 1 1 2 1 1 1 1 1 2 2
Kidney 1 1 1 2 1 2 1 1 1 2 1 1
Liver 1 2 2 2 1 2 1 2 1 1 2 1
Lung 2 2 2 2 1 1 1 1 1 1 1 2
Spleen 1 1 1 2 2 2 1 2 2 2 1 2
Salivary gland ND ND 1 2 ND ND ND 1 2 1 2 2
Note. Four C57BL/6, five C57BL/6b2m
2/2, and two C57BL/6CD82/2 mice were inoculated intraperitoneally with 1.5 3 106 PFU of polyoma virus and
examined for the presence of persistent viral DNA.
a Four C57BL/6 mice were examined for the presence of persistent viral DNA at 9 weeks p.i.
b Of the five b2m
2/2 mice, mice 1–3 developed salivary tumors, and mouse 4 developed hindlimb paralysis, necessitating necropsy at 8–15 weeks
p.i. Mouse 5 remained asymptomatic and was necropsied at 28 weeks p.i.
c Of the three CD82/2 mice, mice 1 and 2 developed hindlimb paralysis at 12–14 weeks p.i., and mouse 3 remained asymptomatic for the duration
of the 22-week study.
ND, not done.
FIG. 3. Detection of polyoma T and VP1 protein message in various
organs of polyoma virus-infected or uninfected C57BL/6 and b2m
2/2
mice in a RT-PCR bioluminescence immunoassay. cDNA from unin-
fected or 9-week p.i. C57BL/6 and b2m
2/2 mice was PCR-amplified for
either 23 cycles (polyoma T protein) or 40 cycles (polyoma VP1) and
then used in the bioluminescence assay with the corresponding probe.
U indicates uninfected mice; I, infected mice.
279POLYOMA TUMOR SUSCEPTIBILITY OF b2m
2/2 MICE
confer protection against polyoma-induced tumors (Alli-
son and Law, 1968; Vandeputte, 1968).
The high tumor incidence in b2m
2/2 mice stands in
contrast to the weak tumorigenicity of polyoma virus in
CD82/2 mice shown here and in another report (Berke et
al., 1996b). Although CD82/2 and b2m
2/2 mice might be
expected to show comparable defects in MHC class
I-restricted T cell-dependent antiviral immune re-
sponses, discrepancies in antiviral class I MHC-re-
stricted CTL activity between syngeneic CD82/2 and
b2m
2/2 mice have been reported (Bachmann et al.,
1995). The extent to which the CD8 coreceptor contrib-
utes to TCR affinity for its MHC–peptide ligand depends
on the intrinsic affinity of the TCR itself (Alexander et al.,
1991; Leuscher et al., 1995). A possible explanation, then,
for polyoma tumor resistance in the CD82/2 mice is that
class I MHC-restricted antiviral CTL possessing high-
affinity TCRs dispense with CD8 coreceptors in their
recognition of virus-infected cells.
Defects in natural killer (NK) cell activity in b2m
2/2
mice could also potentially contribute to the high poly-
oma tumor susceptibility in b2m
2/2 mice. Although
b2m
2/2 mice possess normal NK cell numbers, they
have a reduced capacity to recognize class I MHC-
deficient targets both in vivo and in vitro (Raulet et al.,
1997). Another possibility, then, to explain the difference
in polyoma tumor susceptibilities between b2m
2/2 and
CD82/2 mice is that CD82/2, but not b2m
2/2, mice
mount NK cell responses that contribute to host defense
against polyoma virus tumorigenesis. Recent studies in
our laboratory have demonstrated direct ex vivo NK cell-
specific cytotoxicity against NK cell-sensitive YAC-1 cells
and cell lines from polyoma virus-induced tumors (A.
Lukacher, unpublished observation). Interestingly, Dalianis
and coworkers (Berke et al., 1996a; Dalianis et al., 1982)
subject mice to low-dose irradiation before polyoma tu-
mor cell challenge, a protocol stated to eliminate NK cell
cytotoxicity and permit tumor growth in naı¨ve mice. An-
other study, however, reported that virus-immunized
mice depleted of NK cells still reject a polyoma tumor
cell challenge (Ljunggren et al., 1994). An antiviral role for
NK cells in polyoma infection remains to be investigated.
A central finding of this study is the persistence of
polyoma virus infection in immunocompetent adult
C57BL/6 mice. The emergence of polyoma T and VP1
protein-positive osteosarcomas in 2 of 20 normal
C57BL/6 mice clearly confirms persistence of polyoma
virus DNA. Long-term persistence of papovavirus DNA,
in the face of antiviral CD81 T cells, has also been
recently documented in the cottontail rabbit papillomavi-
rus model, where PCR-amplifiable viral DNA was de-
tected for several months p.i. at sites of completely re-
gressed papillomas (Selvakumar et al., 1997).
Other studies using a variety of techniques have failed
to detect persistent polyoma virus infection in immuno-
competent as well as in immunocompromised mice.
Studies using in situ hybridization of whole mouse sec-
tions and Southern blotting of tissues taken from infected
immunocompetent adult mice did not detect polyoma
virus DNA at 4 weeks p.i. (Wirth et al., 1992). Although
assay sensitivity may account for this inability to detect
viral DNA, other studies using PCR analysis also failed to
amplify polyoma virus DNA from infected normal adult
mice (Berke and Dalianis, 1993; Berke et al., 1995). We
were also unable to detect polyoma virus DNA in organs
from infected mice by Southern blotting or to consistently
PCR-amplify viral DNA with conventional thermocycling
protocols (data not shown). By subjecting template DNA
to a multicycle denaturation protocol (see Materials and
Methods), which presumably eliminates genomic DNA
secondary structures and increases accessibility for
PCR primers and enzymes, before PCR amplification, we
reliably and reproducibly amplified PCR products of the
expected size from multiple organs of persistently in-
fected mice. We also compared our polyoma virus DNA
primers with those used by Berke and Dalianis (1993)
and Berke et al. (1994, 1995, 1996b) for their sensitivity in
detecting viral DNA. Using either the modified or con-
ventional thermocycling protocols, we found that the
primer set used by these researchers amplified polyoma
virus DNA from only a small number of the organ sam-
ples that were positive when using our primer set (data
not shown). A possible explanation for this difference in
detection sensitivity is that the reverse primer used by
Berke and coworkers binds multiple sites on the poly-
oma virus genome and has weak stability for its intended
binding site (Amplify 1.0, Bill Engels, University of Wis-
consin, Madison, WI).
In addition to detecting viral DNA in multiple tissues,
we have shown that early and late polyoma protein
messages are present as late as 9 weeks p.i. in C57BL/6
and b2m
2/2 mice. The presence of VP1 protein message
indicates productive virus infection in both mouse strains
(Atencio et al., 1993). Although virus persists in normal
C57BL/6 mice, the level of infection is lower than in
b2m
2/2 mice, as illustrated by higher T protein message
levels in b2m
2/2 than in C57BL/6 mice and immunohis-
tochemical detection of VP1 in the kidneys of b2m
2/2
mice but not C57BL/6 mice. In view of the rarity of
VP1-positive cells in the kidneys of virus-infected b2m
2/2
mice, we were not surprised by our inability to detect VP1
protein in the kidneys from either virus-infected b2m
2/2
or C57BL/6 mice by Western immunoassays.
The presence of polyoma virus VP1 message in the
organs of C57BL/6 mice, despite the absence of detect-
able VP1 protein by immunohistochemical analysis, re-
flects the high sensitivity of bioluminescence RT-PCR.
Using bioluminescence RT-PCR, Siddiqi et al. (1996) have
shown that PCR products can be detected at 10–15 lower
cycles of PCR amplification than required for ethidium
bromide staining. Bioluminescence RT-PCR is $100-fold
more sensitive than standard Northern and Southern
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blotting techniques. As little as 0.05 pg of template cDNA
can be detected by bioluminescence RT-PCR (Actor and
Hunter, personal communication), whereas $5 pg of a
particular mRNA is needed for detection by Northern
blotting and 0.5–1.5 pg of a particular DNA is needed for
detection by Southern blotting techniques (Ausubel et al.,
1994).
When inoculated into newborn mice, polyoma virus
lytically infects a wide variety of cell types, of which a
subset are susceptible to neoplastic transformation
(Dawe et al., 1987). Viral replication is higher in tumor-
prone tissues than in tissues refractory to polyoma tu-
morigenesis (Wirth et al., 1997). Because viral replication
is linked to viral gene expression, we hypothesize that
cells harboring highly replicating virus express a higher
surface density of class I MHC–viral peptide complexes
and are consequently more susceptible to CD81 CTL
recognition than are cells with low viral genome copy
numbers. In line with this hypothesis, then, the capacity
of this lytic virus to persist in multiple reservoirs in
immunocompetent mice without tumor outgrowth raises
the interesting possibility that class I MHC-restricted T
cells control the emergence of cells with high levels of
viral gene expression, those likely to undergo neoplastic
transformation, but ignore those below a certain level of
expression.
The nearly exclusive targeting of the salivary gland for
polyoma tumor development in b2m
2/2 mice is interest-
ing given the otherwise broad host range of polyoma
virus tumorigenesis in neonatally infected H-2kMtv-71
mice (Lukacher et al., 1993). Historically, polyoma virus
was isolated from parotid gland tumors arising in mice
bearing a retrovirally induced T cell leukemia (and pre-
sumably T cell immunocompromised) (Dawe et al., 1959;
Gross, 1983). In our own hands, irradiated adult mice
infected with polyoma virus uniformly develop salivary
gland tumors while only rarely developing other tumor
types (Lukacher et al., 1995).
The colocalization of lymphoplasmacytic infiltrates
and VP1 protein in the kidneys of b2m
2/2 mice suggests
an overactivation of the humoral arm of the immune
response to compensate for the defect in the dominant
antiviral cellular (i.e., CD81 CTL) arm. In this connection,
it is interesting to note that mice persistently infected
with LCMV, when given cellular immune therapy, clear
infectious virus from all sites except the kidney, which
likewise exhibits multiple interstitial plasma cell infil-
trates (Ahmed et al., 1987). It is also conceivable that the
lymphoplasmacytic infiltrates directly damage renal tu-
bule epithelium, which on regeneration acquire polyoma
virus permissivity, as evidenced by VP1-positive cells
(Atencio et al., 1993).
Although the generation of antibodies to polyoma T
proteins requires help from CD41 T cells, a recent study
demonstrated that IgM and IgG antibodies are elabo-
rated against polyoma VP1 protein after the adoptive
transfer of B cells into virus-infected SCID mice (Szomo-
lanyi-Tsuda and Welsh, 1996). Presumably, the packing of
VP1 into 72 pentameric units to form the virion capsid
provides the high epitope density necessary to trigger
differentiation of B cells independent of T cell help (Szo-
molanyi-Tsuda and Welsh, 1996). In this polyoma virus-
SCID mouse model, antiviral antibodies limited polyoma
virus replication and an associated myeloproliferative
disease but did not prevent polyoma virus tumorigene-
sis. Although b2m
2/2 mice differ from normal mice in
their serum IgG isotype profiles (Spriggs et al., 1992), we
found similar levels of virus-neutralizing activity in the
sera from b2m
2/2 and syngeneic C57BL/6 mice.
In summary, our results indicate that class I MHC-
restricted CD81 T cells mediate resistance to tumors
induced by polyoma virus. This finding is in line with our
recent studies suggesting that depletion of antiviral
CD81 CTL in H-2k inbred mouse strains expressing the
endogenous Mtv-7 superantigen renders these mice
susceptible to polyoma virus tumorigenesis (Lukacher et
al., 1995). Definition of the in vivo target cell (i.e., infected
and/or transformed cell) for these CTL effectors and the
mechanism or mechanisms used by this lytic DNA virus
to persist in immunocompetent asymptomatic hosts are
critical issues to be explored.
MATERIALS AND METHODS
Animals
C57BL/6b2m
2/2 (6–15 weeks old), C57BL/6CD82/2 (14
weeks old), and C57BL/6 (6–9 weeks old) mice were
purchased from the Jackson Laboratory (Bar Harbor,
ME). Pregnant ICR outbred mice were purchased from
Harlan Spraque-Dawley, Inc. (Indianapolis, IN).
Virus and virus inoculation
Polyoma virus strain A2 was molecularly cloned and
virus stocks were prepared on baby ICR mouse kidney
cells as described elsewhere (Lukacher and Wilson,
1998). Adult mice were injected intraperitoneally with
1.5 3 106 plaque-forming units (PFU) of polyoma virus.
Histological examination
Beginning at 4 weeks p.i., mice were monitored bi-
weekly for the development of palpable tumors. When
tumors became .1 cm in diameter, the mice were killed,
full necropsies were performed, and the organs were
fixed in 10% neutral-buffered formalin. Fixed tissues were
paraffin-embedded, and serial 5-mm sections were
stained with Harris’ hematoxylin and eosin.
Analysis of polyoma virus DNA
DNA was extracted from 25 mg of formalin-fixed or
snap-frozen tissue using the QIAamp Tissue Kit (Qiagen,
Chatsworth, CA) according to the manufacturer’s instruc-
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tions. PCR amplification was performed in a 25-ml reac-
tion containing 50 ng of genomic DNA, 0.2 mM concen-
trations of dNTPs, 1.5 mM MgCl2, 13 PCR buffer, 1 U of
Taq DNA polymerase (reagents from GIBCO BRL, Gaith-
ersburg, MD), and 0.2 mM concentration each of 59-
CCTGGCCTCCGCTTACTCT-39 sense primer, corre-
sponding to nucleotide sequence 8–26, and 59-TTTGTCT-
GGGTG CATAGCA-39 antisense primer, corresponding to
the nucleotide sequence 290–309 of the polyoma virus
A2 strain genomic sequence (GenBank accession no.
J022088). To confirm the integrity of the genomic DNA, a
330-bp fragment of mouse chromosome 11 was ampli-
fied using the D11MIT52 primer set (Research Genetics,
Huntsville, AL) in a separate PCR using the same con-
ditions as described above. With both PCRs, before the
addition of Taq DNA polymerase, a nine-step thermocy-
cling protocol (65°C, 30 s; 80°C, 30 s; 65°C, 90 s; 97°C,
180 s; 8°C, 60 s; 65°C, 180 s; 97°C, 60 s; 65°C, 60 s;
80°C, 60 s) was performed to increase the efficiency of
PCR amplification. The thermocycling protocol for poly-
oma virus DNA amplification was (1) 95°C, 3 min; (2)
94°C, 1 min; (3) 54°C, 1 min; (4) 72°C, 2 min; (5) go to
step two 39 times; (6) 72°C, 5 min; and (7) hold at 4°C.
The thermocycling protocol for D11MIT52 amplification
was (1) 95°C, 4 min; (2) 94°C, 45 s; (3) 50°C, 45 s; (4)
72°C, 1 min; (5) go to step two 39 times; (6) 72°C, 7 min;
and (7) hold at 4°C. PCR products were electrophoresed
on a 1.5% agarose gel and visualized by ethidium bro-
mide staining.
RT-PCR bioluminescence immunoassay for detection
of polyoma T and VP1 protein messages
Polyoma T protein and VP1 mRNA levels were deter-
mined using the RT-PCR bioluminescence immunoassay
described by Siddiqi et al. (1996) and Actor et al. (1998),
with the following modifications. RNA was extracted from
snap-frozen, homogenized tissues using Trizol reagent
(GIBCO BRL), reverse-transcribed in a 25-ml mixture con-
taining 1 mg of RNA, 0.25 mM dNTP, 13 first-strand
buffer, 0.8 mM DTT, 200 U of Superscript II (reagents from
GIBCO BRL), 3.2 U of Random Primer (Boehringer-Mann-
heim, Indianapolis, IN), and 20 U of RNAsin (Promega,
Madison, WI) and then adjusted to a 200-ml final volume.
cDNA (5 ml) was PCR-amplified in a 25-ml reaction con-
taining 0.2 mM concentration of dNTPs, 1.5 mM MgCl2, 1
U of Taq DNA polymerase, 13 PCR buffer (reagents from
GIBCO BRL), and 0.2 mM concentration of the following
biotin-conjugated sense primers and nonconjugated an-
tisense primers: b-actin, sense primer 59-ATGGATGAC-
GATATCGCT-39 and antisense primer 59-ATGAGGTAG-
TCTGTCAGGT-39; polyoma T protein, sense primer 59-
GCAGGCATATAAGCAGCAGTC-39 (nucleotides 267–287)
and antisense primer 59-TAGCTGGGGTCCCACTTTC-39
(nucleotides 921–939); polyoma VP1 protein, sense
primer 59-GGACTTGGTCTTTGTTGACCA-39 (nucleotides
3455–3475) and antisense primer 59-GACCTCACCTGT-
GACACCCT-39 (nucleotides 3668–3687 of the polyoma
virus genomic sequence). The thermocycling protocol
was as follows: (1) 95°C, 3 min; (2) 94°C, 1 min; (3) 54°C,
1 min; (4) 72°C, 2 min; (5) 72°C, 5 min; and (6) hold at
4°C. Twenty-three cycles were used for amplification of
polyoma T message and 40 cycles were used for ampli-
fication of VP1 message. cDNA from the same tissue
samples were assayed for both T and VP1 protein mes-
sages. To control for potential DNA contamination of the
RNA, mock reverse transcription reactions that lacked
reverse transcriptase were performed, PCR-amplified for
40 cycles using the polyoma T protein primers, resolved
on a 1.5% agarose gel, and visualized by ethidium bro-
mide staining. The 609-bp PCR products were seen only
in the reverse-transcribed RNA samples (data not
shown).
Biotinylated PCR products were denatured and added
to streptavidin-coated microtiter plates (Boehringer-
Mannheim) containing Aqualite hybridization buffer
(Fisher Scientific, Norcross, GA), and the appropriate
probe was labeled with digoxigenin using the oligonu-
cleotide tailing kit (Boehringer-Mannheim), according to
the manufacturer’s instructions. The following probes
were used: b-actin, 59-GGATGGCTACGTACATGGCT-39;
polyoma T protein, 59-TTGTCTGGGTGCAGTAGCAG-39
(nucleotides 289–308 of the polyoma virus A2 strain
genomic sequence; GenBank accession no. J022088);
and polyoma VP1, 59-GGGCTCTGGCTCACTGTTAG-39
(nucleotides 3668–3687). After washing with Aqualite
wash buffer (Fisher Scientific), the wells were incubated
with Aqualite assay buffer (Fisher Scientific) containing
anti-digoxigenin antibody conjugated to the biolumines-
cent molecule aequorin (SeaLite Sciences, Norcross,
GA). After extensive washing, bound aequorin-conju-
gated antibody was detected by flash-type biolumines-
cence using a ML3000 Luminometer (Dynatech Labora-
tories, Chantilly, VA) immediately after the addition of
Aqualite trigger solution (Fisher Scientific). Units of biolu-
minescence are expressed as relative light units (RLUs).
The polyoma protein message RLUs for each tissue
sample were normalized against the b-actin value for
that sample. The normalization factor for a particular
tissue type and mouse strain was calculated using the
following formula: 1/(individual b-actin RLUs/average of
all b-actin RLUs for a particular tissue type and mouse
strain). The normalization factor was then multiplied by
the RLUs obtained for each protein message to give the
normalized value.
Polyoma virus plaque inhibition assay
Twofold serial dilutions of serum from polyoma virus-
infected or uninfected mice were incubated with 5 3 105
PFU of polyoma virus for 1 h at 37°C, and then the
mixture was titered by plaque assay on UC1B cells.
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Serum titers were calculated as the reciprocal of the
highest dilution that gave a 50% reduction in plaque
formation.
Western blot analysis
AG104A cells (provided by H. Schreiber, University of
Chicago, Chicago, IL) infected with polyoma virus at a
high multiplicity of infection for 36 h were solubilized with
Nonidet P-40 lysis buffer (137 mM NaCl, 20 mM Tris–HCl,
pH 8.0, 0.1 mM CaCl2, 1 mM MgCl2, 1% Nonidet P-40, 10%
glycerol, 25 mg/ml leupeptin, 10 mg/ml aprotinin, 0.5 mM
PMSF). Then, 30 mg of protein from either uninfected or
virus-infected AG104A cells was resolved on a 12% re-
ducing SDS–polyacrylamide gel, transferred to nitrocel-
lulose, and immunoblotted with a 1:100 dilution of serum
from uninfected or virus-infected mice or a 1:10 dilution
of culture supernatants of the pan-polyoma virus T pro-
tein monoclonal antibody F4 (Pallas et al., 1986) and a
1:500 dilution of a rabbit anti-polyoma virus VP1 antisera
(Yi et al., 1997). The membranes were incubated with
HRP-conjugated goat anti-mouse IgG (Jackson Immu-
noresearch, West Grove, PA) and/or donkey anti-rabbit
IgG (Amersham, Arlington Heights, IL) followed by Re-
naissance chemiluminescence reagent (DuPont NEN,
Boston, MA) and visualized by autoradiography.
To examine tissues of polyoma virus-infected mice for
the presence of polyoma virus T and VP1 proteins, 10- to
50-mg tissue sections were lysed in Nonidet P-40 lysis
buffer, and 50 to 100 mg of the protein lysates was
resolved on a 12% reducing SDS–polyacrylamide gel.
The membranes were immunoblotted for T proteins with
the F4 monoclonal antibody or VP1 protein with the
rabbit anti-polyoma virus VP1 antisera.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut
into 5-mm sections and dried onto Superfrost PLUS
slides overnight at 37°C. Tissue sections were incubated
with peroxide block, avidin D block, biotin block, and
powerblock solutions (all supplied by Biogenex, San
Ramon, CA) according to the manufacturer’s instructions.
T cells were detected using anti-CD5 monoclonal anti-
body (2.5 mg/ml) and B cells stained using anti-B220
monoclonal antibody (0.5 mg/ml) (PharMingen, San Di-
ego, CA). Rabbit anti-polyoma virus VP1 antisera was
used at a 1:1000 dilution, and staining was performed at
room temperature for 1 h. After labeling with the anti-CD5
or anti-B220 antibodies, sections were stained with a
biotin-conjugated goat anti-rat antibody followed by HRP-
conjugated streptavidin (BioGenex). When rabbit anti-
VP1 antiserum was used as the primary antibody, the
sections were stained with a secondary HRP-conjugated
donkey anti-rabbit antibody (Amersham, Arlington
Heights, IL). The slides were developed using 3,39-
diaminobenzidine tetrahydrochloride (DAB) chromogen
solution, counterstained with Mayer’s hematoxylin, and
covered with Supermount mounting medium (all re-
agents from BioGenex).
Southern blotting
Two mg of EcoRI-digested genomic DNA isolated from
kidneys using a QIAamp Tissue Kit (Qiagen) was re-
solved on a 0.8% agarose (GIBCO BRL) gel. After depuri-
nation in 0.25 N HCl, denaturation in a 0.5 N NaOH–1.5 M
NaCl solution, and neutralization in a 1 M Tris, pH 7.4–1.5
M NaCl solution, the DNA was capillary-transferred to a
nylon membrane (MSI, Westborough, MA), UV cross-
linked, and hybridized with 32P-random-primed linearized
polyoma virus DNA (Multiprime Labeling Kit, Amersham),
washed, and visualized by autoradiography.
Recovery of infectious virus
Tissue samples from uninfected or virus-infected mice
were weighed and homogenized in serum-free Dulbec-
co’s modified Eagle’s medium (Mediatech, Herndon, VA)
using an overhead stirrer (Wheaton, Millville, NJ) and
disposable Teflon pestles (Kontes, Vineland, NJ) at a
weight-to-volume ratio of 100 mg/ml. The homogenates
were frozen and thawed three times, incubated at 42°C
for 30 min, and centrifuged to remove cell debris. The
virus in the supernatants was titered by plaque assay on
BALB/3T3 clone A31 or NIH3T3 cells.
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